ArticleBJUI compass2026
BK virus-associated urothelial carcinoma-A supra-regional cohort of kidney transplant recipients.
Article in BJUI compass, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to study the clinical features, pathological findings, and outcomes of BK virus-associated urothelial carcinoma (UC) in kidney transplant recipients (KTRs). Patients and Methods: The study was conducted in a retrospective cohort of KTRs with histologically confirmed UC managed at a UK supra-regional transplant urology centre from November 2006 to January 2026. BK virus status was determined using polymerase chain reaction (PCR) testing, and tumour samples were assessed for SV40 large T antigen. Patients were stratified by BKV and SV40 status to enable comparison of tumour grade, stage, and other clinicopathological features. Results: 24 KTRs met the inclusion criteria; 11 of whom were BKV+. The mean follow-up time post-UC diagnosis was 7.3 Conclusion: BKV infection in KTRs was associated with aggressive, high-grade UC. Screening and timely adjustment of immunosuppression are essential to protect this at-risk population. Further studies are required to clarify the oncogenic potential of BKV and optimise management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.